JP MORGAN/CALL/BECTON DICKINSON AND CO./230/0.1/20.09.24 Stock

Warrant

DE000JK1PNE7

Market Closed - Börse Stuttgart 05:53:41 2024-06-28 am EDT
1.58 EUR -3.07% Intraday chart for JP MORGAN/CALL/BECTON DICKINSON AND CO./230/0.1/20.09.24
Current month+3.27%
1 month-6.51%
Date Price Change
24-06-28 1.58 -3.07%
24-06-27 1.63 -11.89%
24-06-25 1.85 -10.19%
24-06-24 2.06 0.00%
24-06-21 2.06 +15.73%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 05:53 am EDT

More quotes

Static data

Product typeWarrant Plain-Vanilla
Buy / SellCALL
Underlying BECTON, DICKINSON AND COMPANY
Issuer J.P. Morgan
WKN JK1PNE
ISINDE000JK1PNE7
Date issued 2024-01-25
Strike 230 $
Maturity 2024-09-20 (84 Days)
Parity 10 : 1
Emission price 2.22
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 3.33
Lowest since issue 1.46
Spread 0.09
Spread %4.95%

Company Profile

Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows: - medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.; - diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.; - clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc. Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
Sector
-
More about the company

Ratings for Becton, Dickinson and Company

Trading Rating
Investor Rating
ESG Refinitiv
A
More Ratings

Consensus: Becton, Dickinson and Company

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
233.7 USD
Average target price
279.2 USD
Spread / Average Target
+19.46%
Consensus